Want to join the conversation?
Biopharma company $KIN said it has submitted the Effectiveness Technical Section of the New Animal Drug Application for Mirataz ointment to the FDA for managing weight loss in cats. Company plans to submit the Safety Technical Section in 3Q16. Based on safety data review, the drug appears to be well tolerated.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.